Minerva Neurosciences, Inc. Revenue
Minerva Neurosciences, Inc. (NERV) reported Revenue of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-02-25
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-12-31 was $0.00.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-09-30 was $0.00.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-03-31 was $0.00.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
- Minerva Neurosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-25 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | $0.00 derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $0.00 10-Q · filed 2021-08-02 | $0.00 derived: sum of 3 quarters · filed 2021-08-02 | $0.00 derived: sum of 4 quarters · filed 2021-08-02 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | $0.00 derived: sum of 2 quarters · filed 2021-05-12 | $0.00 derived: sum of 3 quarters · filed 2021-05-12 | $41.18M derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $41.18M derived: sum of 3 quarters · filed 2021-03-08 | $0.00 10-K · filed 2021-03-08 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $41.18M derived: sum of 2 quarters · filed 2021-03-08 | $0.00 10-Q · filed 2020-11-02 | $41.18M derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-06-30 | $41.18M 10-K · filed 2021-03-08 | $0.00 10-Q · filed 2020-08-03 | $41.18M derived: sum of 3 quarters · filed 2021-03-08 | $41.18M derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-04 | $0.00 derived: sum of 2 quarters · filed 2020-05-04 | $0.00 derived: sum of 3 quarters · filed 2020-05-04 | $0.00 derived: sum of 4 quarters · filed 2020-05-04 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $0.00 derived: sum of 2 quarters · filed 2020-03-09 | $0.00 derived: sum of 3 quarters · filed 2020-03-09 | $0.00 10-K · filed 2020-03-09 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $0.00 derived: sum of 2 quarters · filed 2019-11-04 | $0.00 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-06 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |